204 related articles for article (PubMed ID: 38700863)
1. Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults.
Lee S; Byun MS; Yi D; Ahn H; Jung G; Jung JH; Chang YY; Kim K; Choi H; Choi J; Lee JY; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY;
JAMA Netw Open; 2024 May; 7(5):e249539. PubMed ID: 38700863
[TBL] [Abstract][Full Text] [Related]
2. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
4. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
7. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
[TBL] [Abstract][Full Text] [Related]
8. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
10. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
12. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
[TBL] [Abstract][Full Text] [Related]
13. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
15. The associations between nutritional status and physical frailty and Alzheimer's disease plasma biomarkers in older cognitively unimpaired adults with positive of amyloid-β PET.
Chu H; Huang C; Guan Y; Xie F; Chen M; Guo Q
Clin Nutr; 2024 Jul; 43(7):1647-1656. PubMed ID: 38810424
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
18. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
19. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
20. Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography.
Coughlan GT; Betthauser TJ; Boyle R; Koscik RL; Klinger HM; Chibnik LB; Jonaitis EM; Yau WW; Wenzel A; Christian BT; Gleason CE; Saelzler UG; Properzi MJ; Schultz AP; Hanseeuw BJ; Manson JE; Rentz DM; Johnson KA; Sperling R; Johnson SC; Buckley RF
JAMA Neurol; 2023 May; 80(5):462-473. PubMed ID: 37010830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
